BNP Paribas Financial Markets’s Iovance Biotherapeutics IOVA Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2026
Q2 | $440K | Sell |
105,837
-267,302
| -72% | -$1.02M | ﹤0.01% | 3833 |
|
|
2026
Q1 | $1.31M | Buy |
373,139
+346,352
| +1,293% | +$1.11M | ﹤0.01% | 2953 |
|
|
2025
Q4 | $73.1K | Sell |
26,787
-27,566
| -51% | -$63.8K | ﹤0.01% | 4513 |
|
|
2025
Q3 | $118K | Buy |
54,353
+12,730
| +31% | +$30.1K | ﹤0.01% | 4221 |
|
|
2025
Q2 | $71.6K | Buy |
41,623
+18,471
| +80% | +$46K | ﹤0.01% | 4129 |
|
|
2025
Q1 | $77.1K | Sell |
23,152
-30,129
| -57% | -$155K | ﹤0.01% | 4137 |
|
|
2024
Q4 | $394K | Sell |
53,281
-60,443
| -53% | -$560K | ﹤0.01% | 3441 |
|
|
2024
Q3 | $1.07M | Sell |
113,724
-350,328
| -75% | -$3.32M | ﹤0.01% | 2457 |
|
|
2024
Q2 | $3.72M | Buy |
464,052
+318,128
| +218% | +$3.41M | ﹤0.01% | 1562 |
|
|
2024
Q1 | $2.16M | Sell |
145,924
-406,923
| -74% | -$4.74M | ﹤0.01% | 2004 |
|
|
2023
Q4 | $4.49M | Buy |
552,847
+251,536
| +83% | +$1.32M | 0.01% | 1473 |
|
|
2023
Q3 | $1.37M | Buy |
301,311
+95,953
| +47% | +$626K | ﹤0.01% | 2121 |
|
|
2023
Q2 | $1.45M | Sell |
205,358
-179,659
| -47% | -$1.29M | ﹤0.01% | 1961 |
|
|
2023
Q1 | $2.35M | Sell |
385,017
-25,316
| -6% | -$175K | ﹤0.01% | 1709 |
|
|
2022
Q4 | $2.62M | Buy |
410,333
+246
| +0.1% | +$1.92K | ﹤0.01% | 1620 |
|
|
2022
Q3 | $3.93M | Buy |
410,087
+297,053
| +263% | +$3.43M | 0.01% | 1496 |
|
|
2022
Q2 | $1.25M | Sell |
113,034
-80,281
| -42% | -$1.05M | ﹤0.01% | 2055 |
|
|
2022
Q1 | $3.22M | Buy |
193,315
+152,859
| +378% | +$2.36M | ﹤0.01% | 1527 |
|
|
2021
Q4 | $772K | Sell |
40,456
-30,919
| -43% | -$681K | ﹤0.01% | 2767 |
|
|
2021
Q3 | $1.76M | Buy |
71,375
+69,098
| +3,035% | +$1.63M | ﹤0.01% | 1994 |
|
|
2021
Q2 | $59.2K | Sell |
2,277
-4,689
| -67% | -$122K | ﹤0.01% | 3201 |
|
|
2021
Q1 | $221K | Buy |
6,966
+2,025
| +41% | +$83.9K | ﹤0.01% | 2997 |
|
|
2020
Q4 | $229K | Buy |
4,941
+1,268
| +35% | +$50.3K | ﹤0.01% | 2818 |
|
|
2020
Q3 | $121K | Sell |
3,673
-31,795
| -90% | -$975K | ﹤0.01% | 3014 |
|
|
2020
Q2 | $974K | Sell |
35,468
-21,536
| -38% | -$708K | ﹤0.01% | 1821 |
|
|
2020
Q1 | $1.71M | Buy |
57,004
+40,655
| +249% | +$1.08M | ﹤0.01% | 1578 |
|
|
2019
Q4 | $453K | Sell |
16,349
-4,400
| -21% | -$100K | ﹤0.01% | 2513 |
|
|
2019
Q3 | $378K | Buy |
20,749
+7,684
| +59% | +$170K | ﹤0.01% | 2363 |
|
|
2019
Q2 | $320K | Sell |
13,065
-8,935
| -41% | -$135K | ﹤0.01% | 2303 |
|
|
2019
Q1 | $209K | Buy |
+22,000
| New | +$214K | ﹤0.01% | 2672 |
|
|
2018
Q4 | – | Sell |
-2,690
| Closed | -$30.3K | – | 4374 |
|
|
2018
Q3 | $30.3K | Hold |
2,690
| – | – | ﹤0.01% | 3240 |
|
|
2018
Q2 | $34.4K | Sell |
2,690
-12,151
| -82% | -$178K | ﹤0.01% | 3273 |
|
|
2018
Q1 | $251K | Buy |
14,841
+2,337
| +19% | +$35.4K | ﹤0.01% | 2671 |
|
|
2017
Q4 | $100K | Buy |
12,504
+6,366
| +104% | +$51.1K | ﹤0.01% | 3307 |
|
|
2017
Q3 | $47.6K | Sell |
6,138
-304
| -5% | -$1.92K | ﹤0.01% | 3173 |
|
|
2017
Q2 | $47.3K | Buy |
6,442
+5,994
| +1,338% | +$38.1K | ﹤0.01% | 3227 |
|
|
2017
Q1 | $3.34K | Sell |
448
-2,820
| -86% | -$20.7K | ﹤0.01% | 3396 |
|
|
2016
Q4 | $22.7K | Sell |
3,268
-464
| -12% | -$3.19K | ﹤0.01% | 3129 |
|
|
2016
Q3 | $30.7K | Buy |
3,732
+1,970
| +112% | +$16.7K | ﹤0.01% | 2667 |
|
|
2016
Q2 | $14.3K | Buy |
+1,762
| New | +$11.1K | ﹤0.01% | 2731 |
|
|
2016
Q1 | – | Sell |
-4,462
| Closed | -$34.4K | – | 2869 |
|
|
2015
Q4 | $34.4K | Sell |
4,462
-5,509
| -55% | -$38.2K | ﹤0.01% | 2541 |
|
|
2015
Q3 | $57.4K | Buy |
9,971
+6,224
| +166% | +$48.5K | ﹤0.01% | 2760 |
|
|
2015
Q2 | $34.4K | Buy |
+3,747
| New | +$41.8K | ﹤0.01% | 2715 |
|
Other funds holding IOVA
MFM
PAI
BNP Paribas Financial Markets's IOVA Position: Q2 2026 in Review
BNP Paribas Financial Markets reduced its Iovance Biotherapeutics (IOVA) stake by 72% in Q2 2026, selling an estimated $1.02M and leaving 105,837 shares worth $440K. The position accounts for ﹤0.01% of the portfolio, ranked #3833.
BNP Paribas Financial Markets first reported a position in IOVA in Q2 2015 and has held it in 43 quarters since. The position peaked at $4.49M in Q4 2023. 292 funds tracked by Wall St. Rank hold IOVA as of Q2 2026.
- BNP Paribas Financial Markets held 105,837 shares of Iovance Biotherapeutics worth $440K as of Q2 2026.
- BNP Paribas Financial Markets sold 267,302 Iovance Biotherapeutics shares in Q2 2026, an estimated $1.02M.
- Iovance Biotherapeutics made up ﹤0.01% of BNP Paribas Financial Markets's portfolio in Q2 2026, its #3833 holding.
- BNP Paribas Financial Markets first reported a position in Iovance Biotherapeutics in Q2 2015 and has held it in 43 quarters since.
- BNP Paribas Financial Markets's Iovance Biotherapeutics position peaked at $4.49M in Q4 2023.
- 292 funds tracked by Wall St. Rank held Iovance Biotherapeutics as of Q2 2026.
Based on BNP Paribas Financial Markets's 13F filing for Q2 2026, filed 13 Aug 2026.